Gudgin Dickson E F, Goyan R L, Pottier R H
Department of Chemistry and Chemical Engineering, The Royal Military College of Canada, P.O. Box 17000, Station Forces, Kingston, Ontario, Canada K7K 7B4.
Cell Mol Biol (Noisy-le-grand). 2002 Dec;48(8):939-54.
Photodynamic therapy (PDT), a treatment approach that makes use of a photosensitizer to generate a localized toxic species in diseased tissue, has recently become an approved treatment modality. So far, however, only a handful of photosensitizers have received regulatory approval and for a small number of diseases. This chapter outlines the major limitations of PDT and speculates on the possible improvements that are required in order to advance PDT to a front line therapy. Seven areas of improvements are discussed: drug selectivity, drug delivery, light delivery, combination therapies, pigmented tumors, other potential uses, and protocol optimization. For each area, current limitations are discussed, and further required studies are recommended.
光动力疗法(PDT)是一种利用光敏剂在病变组织中产生局部毒性物质的治疗方法,最近已成为一种获批的治疗方式。然而,到目前为止,只有少数光敏剂获得了监管批准,且仅用于少数几种疾病。本章概述了光动力疗法的主要局限性,并推测了为将光动力疗法推进到一线治疗所需的可能改进措施。讨论了七个改进领域:药物选择性、药物递送、光递送、联合疗法、色素性肿瘤、其他潜在用途和方案优化。针对每个领域,讨论了当前的局限性,并推荐了进一步所需的研究。